[redacted]

Form 39A [See Rule 150E(f)] Under the Drugs and Cosmetics Act 1940 and the Rules thereunder

Sample Name #	MONTELUKAST AND LEVOCETRIZINE DISPERSILBLE TABLETS	**Report No.**	[redacted]
Mfd. By#	NA	**Mfg. Lic. No.#**	
Supplied By#	NA	**Date of Receipt**	16/09/2024
Submitted By Address	MEGHALAYAN MEDICAL DRUGS AND SERVICES NEW COLONY SHILLONG, DHS LAITUMKHRAH, OFFICE OF THE MANAGING DIRECTOR MMSDSL EAST	**Sample Qty.#**	60 TABLETS
		Batch Size#	NA
		Mfg.Date#	03/2024
Ref. No.#	N/A	**Exp.Date#**	02/2026
Batch No.#	MMDSL/QC/-0487		

NS

Date of **Start of Analysis** : 16/09/2024 **Date of Completion of Analysis** : 22/09/2024

RESULTS OF ANALYSIS

Reference to Protocol : IHS

DESCRIPTION : White coloured round shaped biconvex uncoated tablet scored on one side and other side plain.

S.No.	PARAMETERS/TEST	RESULTS	LIMIT
1	IDENTIFICATION	Complies	
2	AVERAGE WEIGHT	180.24 mg	
3	UNIFORMITY OF WEIGHT	Within Limit	± 7.5%
4	DISINTEGRATION TIME	1 Min. 48 Sec.	NMT 3 min.
5	UNIFORMITY OF DISPERSION	Complies	
6	ASSAY (BY HPLC)	Each Dispersible Tablet Contains.	

COMPOSITION	RESULTS	LABEL CLAIM	LIMITS	PROTOCOL
Montelukast Sodium IP Eq. to Montelukast	3.96 mg	4 mg	3.6mg to 4.4mg	IHS
Levocetirizine Dihydrochloride IP	2.46 mg	2.5 mg	2.25 to 2.75mg	IHS

Remarks : In the opinion of the undersigned,the sample referred above is of standard quality as defined in the Drugs Act 1940 and Rules made their under for the reasons given below as per IHS
Sample consume in Testing.

*****END OF REPORT*****

Represents Customer Defined Fields

[redacted]

[redacted]

Date of Issue :13/11/2024

Note:-

1. Sample (s) not drawn by us unless otherwise stated.
2. Total liability of our analytical division is limited to the invoiced amount.
3. Sample will be destroyed after one month from the date of issue of test certificate unless otherwise specified.
4. Test certificate in full or parts shall not be use for promotional or publicity purpose.
5. Result given in report in related to sample tested only.